SCHEMBL19619262

SCHEMBL19619262

NCC1OC(OC2C(O)C(N)CC(N)C2OC2OC(CO)C(O)C(O)C2N)C(O)C1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 1.00
TSHR P16473 2/20 0.91
HSD17B10 Q99714 1/20 0.91
LRAT O95237 2/20 0.88
MEN1 O00255 2/20 0.88
TRPV1 Q8NER1 1/20 0.88
BLM P54132 1/20 0.81
RECQL P46063 1/20 0.81
TDP1 Q9NUW8 1/20 0.81
KDM4E B2RXH2 1/20 0.78
ALOX15 P16050 1/20 0.78
GJA1 P17302 1/20 0.72
GJB2 P29033 1/20 0.72
CYP2C9 P11712 1/20 0.72
KMT2A Q03164 1/20 0.72
ALDH1A1 P00352 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribostamycin SCHEMBL48820 1.00 LMNA (1.00) LMNATSHRHSD17B10LRATMEN1
Ribostamycin SCHEMBL13599669 1.00 LMNA (1.00) LMNATSHRHSD17B10LRATMEN1
Ribostamycin SCHEMBL19944115 1.00 LMNA (1.00) LMNATSHRHSD17B10LRATMEN1
Ribostamycin SCHEMBL13605470 1.00 LMNA (1.00) LMNATSHRHSD17B10LRATMEN1
Ribostamycin SCHEMBL15432715 1.00 LMNA (1.00) LMNATSHRHSD17B10LRATMEN1
SCHEMBL19619289 1.00 LMNA (1.00) LMNATSHRHSD17B10LRATMEN1
SCHEMBL17321247 1.00 LMNA (1.00) LMNATSHRHSD17B10LRATMEN1
SCHEMBL16882157 1.00 LMNA (1.00) LMNATSHRHSD17B10LRATMEN1
Ribostamycin SCHEMBL20530016 1.00 LMNA (1.00) LMNATSHRHSD17B10LRATMEN1
Ribostamycin SCHEMBL48819 1.00 LMNA (1.00) LMNATSHRHSD17B10LRATMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11613551-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders ELOXX PHARMACEUTICALS LTD. (IL) 2023-03-28 US disclosed
US-20210300958-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS ELOXX PHARMACEUTICALS LTD. (IL) 2021-09-30 US disclosed
US-20190016746-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS ELOXX PHARMACEUTICALS LTD. (IL) 2019-01-17 US disclosed
US-20180064743-A1 NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2018-03-08 US disclosed
US-9821001-B2 Aminoglycosides and uses thereof in the treatment of genetic disorders TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2017-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064743-A1 NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS AARS1, NARS1, GOT1 LMNA 1943/4885TSHR 4748/4885HSD17B10 1220/4885
US-20210300958-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS UPF1, AARS1, NUDT21 LMNA 1286/4885TSHR 3306/4885HSD17B10 2322/4885
US-20190016746-A1 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS UPF1, AARS1, GET3 LMNA 1125/4885TSHR 3016/4885HSD17B10 2856/4885
US-11613551-B2 Aminoglycoside derivatives and uses thereof in treating genetic disorders UPF1, AARS1, NUDT21 LMNA 1286/4885TSHR 3306/4885HSD17B10 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.